KLK6抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P01503(KLK6 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P01503(KLK6 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

KLK6 (kallikrein-related peptidase 6) is a serine protease belonging to the human tissue kallikrein family, encoded by the *KLK6* gene. It is involved in diverse physiological processes, including extracellular matrix remodeling, inflammation, and cellular signaling. KLK6 is expressed in various tissues, such as the central nervous system, pancreas, and ovaries, and is implicated in both health and disease. Notably, elevated KLK6 levels are observed in cancers (e.g., glioblastoma, colorectal, and ovarian cancers), where it promotes tumor progression, invasion, and metastasis by modulating pathways like EGFR and integrin signaling. Conversely, in neurodegenerative disorders like Alzheimer’s disease and multiple sclerosis, KLK6 dysregulation correlates with neuroinflammation and neuronal damage.

KLK6 antibodies are essential tools for detecting and studying this protease in research and diagnostics. They enable the quantification and localization of KLK6 in biological samples using techniques such as Western blotting, immunohistochemistry, and ELISA. Specific monoclonal or polyclonal antibodies help elucidate KLK6's role in disease mechanisms, evaluate its potential as a biomarker, or explore therapeutic targeting. For example, antibodies blocking KLK6 activity are investigated for their anti-tumor effects. However, challenges remain in ensuring antibody specificity due to structural similarities among kallikrein family members. Ongoing research aims to refine antibody design and expand applications in translational medicine.